Tv changes in eCPMV-treated and control dogs
| Patient | Day | eCPMV dose, mg | Treatments | Tv, cm3 | %TGI | P value |
| P1 (T1) | D0 | 0.200 | 8 | 67.4 | 0.0 | |
| D7 | 0.200 | 49.5 | −26.5 | |||
| D19 | 0.200 | 36.9 | −45.3 | 0.063 | ||
| DFU | 13.2 | −80.4 | 0.007 | |||
| P1 (T2) | D0 | 6 | 7.4 | 0.0 | ||
| D7 | 10.0 | 35.1 | ||||
| D19 | 0.200 | 17.8 | 140.7 | 0.179 | ||
| DFU | 5.2 | −29.7 | 0.977 | |||
| P2 (T1) | D0 | 0.350 | 7 | 39.6 | 0.0 | |
| D7 | 0.350 | 28.6 | −27.8 | |||
| D14 | 0.350 | 23.6 | −40.4 | 0.137 | ||
| DFU | 0.350 | 43.1 | 8.9 | 0.920 | ||
| P2 (T2) | D0 | 0.050 | 7 | 6.1 | 0.0 | |
| D7 | 0.050 | 2.1 | −64.9 | |||
| D14 | 0.050 | 0.7 | −89.3 | 0.163 | ||
| DFU | 0.050 | 2.9 | −52.3 | 0.379 | ||
| P3 | D0 | 0.400 | 2 | 104.2 | 0.0 | |
| D7 | 0.400 | 25.2 | −75.8 | |||
| D14 | 24.7 | −76.3 | 0.330 | |||
| P4 | D0 | 0.400 | 3 | 52.7 | 0.0 | |
| D7 | 0.400 | 61.4 | 16.6 | |||
| D15 | 0.400 | 51.0 | −3.1 | 0.907 | ||
| P5 | D0 | 0.200 | 2 | 4.3 | 0.0 | |
| D9 | 0.200 | 4.5 | 3.5 | |||
| D17 | 4.2 | −3.5 | 0.667 | |||
| Control canine IMC patients | ||||||
| P6 | D0 | 252.0 | ||||
| D25 | 459.0 | 82.2 | ||||
| P7 | D0 | 14.0 | ||||
| NA | NA | |||||
| P8 | D0 | 32.0 | ||||
| D73 | 75.3 | 124.6 | ||||
| P9 | D0 | 30.6 | ||||
| D35 | 94.6 | 209.0 | ||||
| P10 | D0 | 9.4 | ||||
| D39 | 30.8 | 228.6 | ||||
D0, D7, D14, DFU, day 0, 7, 14 and at last follow-up (D92 in P1 and D79 in P2), respectively; T1, target tumor; T2, second tumor treated; NA, not available; Treatments refer to the total number of eCPMV injections; %TGI, percentage of tumor growth inhibition. P values obtained by regression analysis as described in Methods. The first P value shows regression analysis from D0 to D14; the second, from D0 to last follow-up.
DFU, date of follow-up; eCPMV, empty cowpea mosaic virus; NA, not available; TGI, tumor growth inhibition; Tv, tumor volume.